Global Lymphoma Drugs Market 2017-2021


◆タイトル:Global Lymphoma Drugs Market 2017-2021
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆資料形式:PDF / 英語
Single User(1名利用)USD3,500 ⇒換算¥385,000見積依頼/購入/質問フォーム
Five User(~5名利用)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD5,000 ⇒換算¥550,000見積依頼/購入/質問フォーム
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。



About Lymphoma DrugsLymphoma is a type of cancer that affects the immune system of the body. Specifically, it affects the lymphocytes, a type of white blood cell. The lymphocytes are part of the immune system and help the body to fight infections. The cancerous lymphocytes grow uncontrollably and collect in different portions of the body; lymph node can be one of the most common sites for lymphoma development. The lymph nodes are found throughout the body particularly in the groin, neck, and under the arms. Lymphoma can also develop in the deeper lymph nodes such as those in bone marrow and spleen. Very rarely this disease can start in other parts of the body such as stomach, breast, skin, brain, bowel, or liver.

Technavio’s analysts forecast the global lymphoma drugs market to grow at a CAGR of 8.02% during the period 2017-2021.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global lymphoma drugs market for 2017-2021. To calculate the market size, the report considers the sales from branded, generic, and off-label drugs.

The market is divided into the following segments based on geography:
• Americas

Technavio’s report, Global Lymphoma Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• Celgene
• F. Hoffmann-La Roche
• Johnson & Johnson
• Seattle Genetics

[Other prominent vendors]
• Amgen
• Bristol-Myers Squibb
• Gilead Sciences
• GlaxoSmithKline
• Novartis
• Pfizer
• Takeda Pharmaceuticals
• Teva Pharmaceutical Industries

[Market driver]
• Increase in industry-academia collaborations
• For a full, detailed list, view our report

[Market challenge]
• High cost of lymphoma treatment
• For a full, detailed list, view our report

[Market trend]
• Increasing consolidation in the cancer treatment market
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

*** You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.


Table of Contents
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction
• Market outline
• Lymphoma disease overview

PART 05: Market Introduction
• Market overview
• Market size and forecast
• Five forces analysis

PART 06: Pipeline landscape

PART 07: Market segmentation by disease type
• HL

PART 08: Geographical segmentation
• Lymphoma drugs market in Americas
• Lymphoma drugs market in EMEA
• Lymphoma drugs market in APAC

PART 09: Decision framework

PART 10: Drivers and challenges
• Market drivers
• Market challenges

PART 11: Market trends
• Increasing consolidation in the cancer treatment market
• Development of rituximab resistance leading to the development of new therapies
• Studies performed to understand the genetics of lymphoma cells

PART 12: Vendor landscape
• Competitive scenario

PART 13: Key vendor analysis
• Celgene
• F. Hoffmann-La Roche
• Johnson & Johnson
• Seattle Genetics
• Other prominent vendors

PART 14: Appendix
• List of abbreviations

[List of Exhibits]
Exhibit 01: Types of lymphoma
Exhibit 02: Tests for lymphoma
Exhibit 03: Stages of lymphoma development
Exhibit 04: Treatment options for lymphoma
Exhibit 05: Global lymphoma drugs market snapshot
Exhibit 06: Global lymphoma drugs market 2016-2021($ millions)
Exhibit 07: Opportunity analysis in global lymphoma drugs market
Exhibit 08: Five forces analysis
Exhibit 09: Key pipeline drugs by vendors
Exhibit 10: Pipeline analysis
Exhibit 11: Segmentation of global lymphoma drugs market by disease type 2016
Exhibit 12: Market share of global lymphoma drugs market based on disease type 2016 and 2021
Exhibit 13: Subtypes of HL
Exhibit 14: Types of classic HL
Exhibit 15: Global HL drugs market 2016-2021 ($ millions)
Exhibit 16: Major drugs involved in HL drugs market
Exhibit 17: Types of NHL
Exhibit 18: Prevalence of various B-cell lymphoma in NHL
Exhibit 19: T-cell and natural killer cell lymphoma types
Exhibit 20: Global NHL drugs market 2016-2021 ($ millions)
Exhibit 21: Key highlights of NHL drugs market
Exhibit 22: Segmentation of global lymphoma drugs market based on geography 2016 and 2021
Exhibit 23: Global lymphoma drugs market revenue by geography 2016-2021 ($ millions)
Exhibit 24: Market scenario in Americas
Exhibit 25: Lymphoma drugs market in Americas 2016-2021 ($ millions)
Exhibit 26: Incidence of NHL in Americas
Exhibit 27: Market scenario in EMEA
Exhibit 28: Lymphoma drugs market in EMEA 2016-2021 ($ millions)
Exhibit 29: Lymphoma cases in UK 2014
Exhibit 30: Incidence of NHL in EMEA
Exhibit 31: Market scenario in APAC
Exhibit 32: Lymphoma drugs market in APAC 2016-2021 ($ millions)
Exhibit 33: Incidence of NHL in APAC
Exhibit 34: Grants for research projects for NHL compared with total cancer researches 2016
Exhibit 35: Drugs and associated side effects
Exhibit 36: Competitive structure analysis of global lymphoma drugs market 2016
Exhibit 37: Strategic success factors of companies in global lymphoma drugs market
Exhibit 38: Celgene: Key highlights
Exhibit 39: Celgene: Strength assessment
Exhibit 40: Celgene: Strategy assessment
Exhibit 41: Celgene: Opportunity assessment
Exhibit 42: F. Hoffmann-La Roche: Key highlights
Exhibit 43: F. Hoffmann-La Roche: Strength assessment
Exhibit 44: F. Hoffmann-La Roche: Strategy assessment
Exhibit 45: Johnson & Johnson: Opportunity assessment
Exhibit 46: Johnson & Johnson: Key highlights
Exhibit 47: Johnson & Johnson: Strength assessment
Exhibit 48: Johnson & Johnson: Strategy assessment
Exhibit 49: Johnson & Johnson: Opportunity assessment
Exhibit 50: Seattle Genetics: Key highlights
Exhibit 51: Seattle Genetics: Strength assessment
Exhibit 52: Seattle Genetics: Strategy assessment
Exhibit 53: Seattle Genetics: Opportunity assessment


Celgene, F. Hoffmann-La Roche, Johnson & Johnson, Seattle Genetics, Amgen, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Novartis, Pfizer, Takeda Pharmaceuticals, and Teva Pharmaceutical Industries.





★調査レポート[リンパ腫治療薬の世界市場2017-2021] (Global Lymphoma Drugs Market 2017-2021 / IRTNTR12892)販売に関する免責事項
[リンパ腫治療薬の世界市場2017-2021] (Global Lymphoma Drugs Market 2017-2021 / IRTNTR12892)についてEメールでお問い合わせ